Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 81
2.
Curr Hypertens Rep ; 25(11): 353-363, 2023 11.
Article En | MEDLINE | ID: mdl-37672130

PURPOSE OF REVIEW: This narrative review aims to assess the pathophysiology, diagnosis, and treatment of resistant hypertension (RH) in end-stage kidney disease (ESKD) patients on dialysis, with a specific focus on the effect of renal denervation (RDN) on short-term and long-term blood pressure (BP) control. Additionally, we share our experience with the use of RDN in an amyloidotic patient undergoing hemodialysis with RH. RECENT FINDINGS: High BP, an important modifiable cardiovascular risk factor, is often observed in patients in ESKD, despite the administration of multiple antihypertensive medications. However, in clinical practice, it remains challenging to identify RH patients on dialysis treatment because of the absence of specific definition for RH in this context. Moreover, the use of invasive approaches, such as RDN, to treat RH is limited by the exclusion of patients with reduced renal function (eGFR < 45 mL/min/1.73 m3) in the clinical trials. Nevertheless, recent studies have reported encouraging results regarding the effectiveness of RDN in stage 3 and 4 chronic kidney disease (CKD) and ESKD patients on dialysis, with reductions in BP of nearly up to 10 mmhg. Although multiple underlying pathophysiological mechanisms contribute to RH, the overactivation of the sympathetic nervous system in ESKD patients on dialysis plays a crucial role. The diagnosis of RH requires both confirmation of adherence to antihypertensive therapy and the presence of uncontrolled BP values by ambulatory BP monitoring or home BP monitoring. Treatment involves a combination of nonpharmacological approaches (such as dry weight reduction, sodium restriction, dialysate sodium concentration reduction, and exercise) and pharmacological treatments. A promising approach for managing of RH is based on catheter-based RDN, through radiofrequency, ultrasound, or alcohol infusion, directly targeting on sympathetic overactivity.


Hypertension , Kidney Failure, Chronic , Humans , Antihypertensive Agents/therapeutic use , Kidney , Blood Pressure/physiology , Renal Dialysis , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Denervation , Sodium , Treatment Outcome , Sympathectomy/methods
4.
Biomolecules ; 13(4)2023 03 31.
Article En | MEDLINE | ID: mdl-37189376

Although reduced bone mineral density (BMD) is associated with a higher risk of fractures, morbidity, and mortality in kidney transplant patients (KTRs), there is no consensus on optimal treatment for the alterations of BMD in this population. This study aims at assessing the effect of cholecalciferol supplementation on BMD over a follow-up period of 2 years in a cohort of long-term KTRs. Patients with age ≥ 18 years were included and divided into two subgroups based on treatment with bisphosphonate and/or calcimimetics and/or active vitamin D sterols (KTRs-treated) or never treated with the above medications (KTRs-free). BMD was evaluated at lumbar vertebral bodies (LV) and right femoral neck (FN) with standard DEXA at the beginning and end of the study. According to World Health Organization (WHO) criteria, results were expressed as T-score and Z-score. Osteoporosis and osteopenia were defined as T score ≤ -2.5 SD and T score < -1 and >-2.5 SD, respectively. Cholecalciferol was supplemented at a dose of 25,000 IU/week over 12 weeks followed by 1500 IU/day. KTRs-free (n. 69) and KTRs-treated (n. 49) consecutive outpatients entered the study. KTRs-free were younger (p < 0.05), with a lower prevalence of diabetes (p < 0.05) and of osteopenia at FN (46.3 % vs. 61.2 %) compared to KTRs-treated. At the entry none of the study subjects had a sufficient level of cholecalciferol; Z-score and T-score at LV and FN were not different between groups. At the end of the study period, serum cholecalciferol concentration was significantly increased in both groups (p < 0.001); the KTRs-free group presented an improvement in both T-score and Z-score at LV (p < 0.05) as well as a lower prevalence of osteoporotic cases (21.7% vs. 15.9%); in contrast, no changes were recorded in KTR-treated individuals. In conclusion, supplementation with cholecalciferol ameliorated Z-score and T-score at LV in long-term KTRs who had been never treated with active or inactive vitamin D sterols, bisphosphonates, and calcimimetics. Future endeavours are needed to confirm these preliminary findings.


Bone Diseases, Metabolic , Kidney Transplantation , Humans , Adolescent , Bone Density , Kidney Transplantation/adverse effects , Bone Diseases, Metabolic/drug therapy , Bone Diseases, Metabolic/epidemiology , Bone Diseases, Metabolic/etiology , Diphosphonates/therapeutic use , Cholecalciferol/therapeutic use , Cholecalciferol/pharmacology , Vitamin D/pharmacology , Sterols
5.
Diagnostics (Basel) ; 12(6)2022 Jun 13.
Article En | MEDLINE | ID: mdl-35741264

Although atherosclerotic renal artery stenosis (ARAS) is strictly associated with high cardiovascular risk and mortality, it often may remain unrecognized being clinically silent and frequently masked by co-morbidities especially in elderly patients with coexisting chronic kidney disease (CKD). The present observational study was conducted in elderly CKD-patients with atherosclerosis on other arterial beds. The aims were assessment of (1) ARAS prevalence; (2) best predictor(s) of ARAS, using duplex ultrasound; and (3) cardiovascular and renal outcomes at one-year follow-up. The cohort was represented by 607 consecutive in-patients. Inclusion criteria were age ≥65 years; CKD stages 2−5 not on dialysis; single or multiple atherosclerotic plaque on epiaortic vessels, abdominal aorta, aortic arch, coronary arteries, peripheral arteries that had been previously ascertained by one or more procedures. Duplex ultrasound was used to detect ARAS. Multiple regression analysis and ROS curve were performed to identify the predictors of ARAS. ARAS was found in 53 (44%) out of 120 patients who met the inclusion criteria. In univariate analysis, GFR (b = −0.021; p = 0.02); hemoglobin (b = −0.233; p = 0.02); BMI (b = 0.134; p = 0.036) and atherosclerosis of abdominal aorta and/or peripheral vessels (b = 1.025; p < 0.001) were associated with ARAS. In multivariable analysis, abdominal aorta and/or peripheral atherosclerosis was a significant (p = 0.002) predictor of ARAS. The area under the ROC curve was 0.655 (C.I. = 0.532−0.777; p = 0.019). ARAS is common in older CKD patients with extra-renal atherosclerosis, with the highest prevalence in those with aortic and peripheral atherosclerosis. ARAS may pass by unnoticed in everyday clinical practice.

6.
G Ital Nefrol ; 39(1)2022 Feb 16.
Article It | MEDLINE | ID: mdl-35191624

Ascites is a pathological accumulation of fluid in the peritoneal cavity due to various etiologies, often associated with renal failure. Paracentesis is a simple method of removing ascitic fluid by inserting a needle into the peritoneal cavity, often performed at the patient's bedside. It can be both diagnostic and therapeutic. Ultrasound imaging allows the diagnosis of ascites, the identification of the puncture site on the abdominal wall during the pre-procedural phase, the real time evaluation of the needle and the continuous course of the maneuver. This eco-guide technique has higher effectiveness and lower risk of complications than the "blind" venipuncture technique. Ultrasound-guided paracentesis, when performed by nephrologists, reduces the waiting time both for the execution of paracentesis and for the diagnosis, treatment and follow-up of ascites.


Ascites , Paracentesis , Ascites/diagnostic imaging , Ascites/etiology , Ascites/therapy , Humans , Paracentesis/adverse effects , Paracentesis/methods , Ultrasonography , Ultrasonography, Interventional/adverse effects
7.
G Ital Nefrol ; 38(5)2021 10 26.
Article It | MEDLINE | ID: mdl-34713646

Home dialysis is a primary objective of Italian Ministry of Health. As stated in the National Chronicity Plan and the Address Document for Chronic Renal Disease, it is mostly home hemodialysis and peritoneal dialysis to be carried out in the patient's home. Home hemodialysis has already been used in the past and today has found new technologies and new applications. The patient's autonomy and the need for a caregiver during the sessions are still the main limiting factors. In this multicenter observational study, 7 patients were enrolled for 24 months. They underwent six weekly hemodialysis sessions of 180' each; periodic medical examinations and blood tests were performed (3, 6, 12, 18 and 24 months). After 3-6 months of home hemodialysis there was already an improvement in the control of calcium-phosphorus metabolism (improvement in phosphorus values, (p <0.01), a reduction in parathyroid hormone (p <0.01)); in the number of phosphorus binders used (p <0.02); in blood pressure control (with a reduction in the number of hypotensive drugs p <0.02). Home hemodialysis, although applicable to a small percentage of patients (10-15%), has improved blood pressure control, calcium-phosphorus metabolism and anemia, reducing the need for rhEPO.


Kidney Failure, Chronic , Peritoneal Dialysis , Calcium , Hemodialysis, Home , Humans , Parathyroid Hormone , Phosphorus , Renal Dialysis
8.
Front Med (Lausanne) ; 8: 640876, 2021.
Article En | MEDLINE | ID: mdl-33634157

Fabry Disease (FD), a rare and progressive, X-linked lysosomal storage disorder, is caused by mutations in the α-galactosidase A (GLA) gene which leads to enzymatic deficiency of GLA. Misdiagnosed and undiagnosed FD cases are common for the variable FD phenotype, ranging from asymptomatic and/or impairment of single organs, which is typically seen in females and in patients with late-onset mutation, to multiple organ disease, which is frequently found in males with classic GLA mutation. Consequently, for an early diagnosis and an efficient treatment of FD, three different strategies of screening, new-born screening, high-risk screening and familiar screening, have been conducted. However, most of FD screening in the CKD population has been carried out in hemodialysis patients and kidney transplant recipients, for whom the renal damage is already irreversible, so the effectiveness of enzymatic replacement therapy is limited and delayed therapeutic intervention results in worse long-term outcomes. This review investigates the actual strategies of screening initiatives for the identification of FD, examining in detail those performed in CKD patients not on dialysis.

9.
G Ital Nefrol ; 37(Suppl 75)2020 08 03.
Article It | MEDLINE | ID: mdl-32749088

The correct management of patients with kidney stones is a crucial issue for nephrologists. In recent years, the incidence and prevalence rates of nephrolithiasis have maintained a growing trend worldwide, showing a strong correlation with other systemic disease such as diabetes mellitus, hypertension, obesity, metabolic syndrome and chronic kidney disease. International guidelines indicate computed tomography as the first choice for all adult patients with suspected acute symptoms for obstructive nephrolithiasis. Intravenous pyelogram is more useful in the follow-up of patients with relapsing nephrolithiasis and known stone composition, while the high costs and the long image acquisition times limit the routine use of magnetic resonance. Recent innovative tools have improved the accuracy of kidney stone localization and measuring with B-Mode and color Doppler imaging, thereby reducing the gap between ultrasonography and computer tomography. The aim of this review is to report the latest evidence on risk factors and on the pathophysiology of nephrolithiasis, and to compare the utility of the available imaging techniques in the management of patients with kidney stones, focusing on the role of ultrasonography and the present and future strategies to improve its accuracy.


Kidney Calculi/diagnostic imaging , Nephrolithiasis/diagnostic imaging , Algorithms , Forecasting , Humans , Kidney Calculi/therapy , Nephrolithiasis/therapy , Reproducibility of Results , Ultrasonography/trends
10.
Nutrients ; 12(5)2020 May 12.
Article En | MEDLINE | ID: mdl-32408709

Protein Energy Wasting (PEW) in hemodialysis (HD) patients is a multifactorial condition due to specific pathology-related pathogenetic mechanisms, leading to loss of skeletal muscle mass in HD patients. Computed Tomography and Magnetic Resonance Imaging still represent the gold standard techniques for body composition assessment. However, their widespread application in clinical practice is difficult and body composition evaluation in HD patients is mainly based on conventional anthropometric nutritional indexes and bioelectrical impedance vector analysis (BIVA). Little data is currently available on ultrasound (US)-based measurements of muscle mass and fat tissue in this clinical setting. The purpose of our study is to ascertain: (1) if there are differences between quadriceps rectus femoris muscle (QRFM) thickness and abdominal/thigh subcutaneous fat tissue (SFT) measured by US between HD patients and healthy subjects; (2) if there is any correlation between QRFM and abdominal/thigh SFT thickness by US, and BIVA/conventional nutritional indexes in HD patients. We enrolled 65 consecutive HD patients and 33 healthy subjects. Demographic and laboratory were collected. The malnutrition inflammation score (MIS) was calculated. Using B-mode US system, the QRFM and SFT thicknesses were measured at the level of three landmarks in both thighs (superior anterior iliac spine, upper pole of the patella, the midpoint of the tract included between the previous points). SFT was also measured at the level of the periumbilical point. The mono frequency (50 KHz) BIVA was conducted using bioelectrical measurements (Rz, resistance; Xc, reactance; adjusted for height, Rz/H and Xc/H; PA, phase angle). 58.5% were men and the mean age was 69 (SD 13.7) years. QRFM and thigh SFT thicknesses were reduced in HD patients as compared to healthy subjects (p < 0.01). Similarly, also BIVA parameters, expression of lean body mass, were lower (p < 0.001), except for Rz and Rz/H in HD patients. The average QRFM thickness of both thighs at top, mid, lower landmarks were positively correlated with PA and body cell mass (BCM) by BIVA, while negatively correlated with Rz/H (p < 0.05). Abdominal SFT was positively correlated with PA, BCM and basal metabolic rate (BMR) (p < 0.05). Our study shows that ultrasound QRFM and thigh SFT thicknesses were reduced in HD patients and that muscle ultrasound measurements were significantly correlated with BIVA parameters.


Kidney Failure, Chronic/diagnostic imaging , Quadriceps Muscle/diagnostic imaging , Renal Dialysis/adverse effects , Subcutaneous Fat/diagnostic imaging , Ultrasonography/statistics & numerical data , Aged , Body Composition , Cross-Sectional Studies , Electric Impedance , Female , Humans , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Male , Middle Aged , Quadriceps Muscle/physiopathology , Reproducibility of Results , Subcutaneous Fat/physiopathology
11.
G Ital Nefrol ; 37(2)2020 Apr 09.
Article It | MEDLINE | ID: mdl-32281763

In recent years imaging techniques that use radionuclides have become more and more clinically relevant as they can provide functional information for specific anatomical districts. This has also involved nephrology, where radionuclides are used to study patients with different degrees of renal function failure up to terminal uremia. Although chronic kidney disease, and dialysis in particular, may affect the distribution and the elimination of radiopharmaceuticals, to date there are no consistent data on the risks associated with their use in this clinical context. In addition to the lack of data on the safety of radio-exposure in dialysis patients, there is also a shortage of information concerning the risk for healthcare staff involved in conducting the dialysis sessions performed after a nuclear test. This study, performed on 29 uremic patients who underwent hemodialysis immediately after a scintigraphic examination, assessed the extent of radio-contamination of the staff and of hemodialysis devices such as monitor, kits and dialysate. The data collected has been used to quantify the radiological risk in dialysis after the exposure to the most common radionuclides.


Kidney Failure, Chronic/diagnostic imaging , Radiopharmaceuticals/metabolism , Renal Dialysis , Dialysis Solutions/chemistry , Dialysis Solutions/metabolism , Humans , Kidney Failure, Chronic/metabolism , Radionuclide Imaging/adverse effects , Radionuclide Imaging/methods , Radiopharmaceuticals/adverse effects , Risk Assessment , Uremia/metabolism
12.
G Ital Nefrol ; 37(1)2020 Feb 12.
Article It | MEDLINE | ID: mdl-32068358

The term "obstructive uropathy" refers to the complex structural and functional changes following the interruption of normal urinary runoff, which can occur at every level of the urinary tract. Depending on its origin, duration and severity, urinary tract obstructions can be acute or chronic, mono or bilateral, partial or complete. The obstruction can be localized or extended to the entire pielo-caliceal system and/or homolateral urethra. The term "hydronephrosis" indicates the dilation of the pelvis detected through imaging techniques. Among these, ultrasound is considered the gold standard in the diagnosis of obstructive uropathy: it allows to distinguish three degrees of urinary tract dilation, depending on the extent of the dilation itself and the thickness of the parenchyma. Nephrologists are confronted daily with patients who experience kidney failure and must be able to quickly distinguish between chronic and acute and, in the latter case, to discern between issues of nephrological or urological competence. This short review aims at helping them deal with this very common scenario, through the use of ultrasound.


Acute Kidney Injury/diagnostic imaging , Hydronephrosis/diagnostic imaging , Renal Insufficiency, Chronic/diagnostic imaging , Ultrasonography , Ureteral Obstruction/diagnostic imaging , Urethral Obstruction/diagnostic imaging , Diagnosis, Differential , Dilatation, Pathologic/diagnostic imaging , Echocardiography, Doppler, Color , Humans , Kidney Calices/diagnostic imaging , Kidney Pelvis/diagnostic imaging , Vascular Resistance
13.
Clin Nephrol ; 93(2): 57-64, 2020 Feb.
Article En | MEDLINE | ID: mdl-31319906

Kidney transplant recipients (KTRs) are susceptible to low levels of vitamin D, which may be responsible for mineral and bone metabolism disorders and play some role in the occurrence of cardiovascular, metabolic, immunologic, neoplastic, and infectious complications after kidney transplant. Kidney Disease Improving Global Outcomes (KDIGO) guidelines of the year 2017 recommended vitamin D supplementation in the first 12 months after transplant using the same treatment strategies for the general population. However, no recommendations are provided after the first 12 months due to a lack of sufficient data. This review analyses some studies that assessed the vitamin D status of KTRs and the effects of nutritional and active vitamin D supplementation on bone mineral density, cardiovascular disease, proteinuria, and graft function in KTRs.


Kidney Transplantation , Vitamin D/therapeutic use , Vitamins/therapeutic use , Bone Density , Bone Diseases, Metabolic/prevention & control , Cardiovascular Diseases/prevention & control , Dietary Supplements , Graft Survival/drug effects , Humans , Proteinuria/prevention & control , Vitamin D/administration & dosage , Vitamins/administration & dosage
14.
G Ital Nefrol ; 36(6)2019 Dec 09.
Article It | MEDLINE | ID: mdl-31830390

Central venous catheterization is a procedure frequently performed in daily clinical practice. The use of ultrasound during central venous catheter placement has significantly reduced the number of complications. However, while the outcome of the procedure has significantly improved, the number of legal disputes has increased. Despite the current legislation has repeatedly stressed the importance of adequately collecting informed consent, to date many legal cases show that this procedure is only superficially followed. The objective of the present work is to analyze the various phases of central venous catheterization, with the aim of making useful suggestions to avoid potential medical-legal problems.


Catheterization, Central Venous/adverse effects , Liability, Legal , Humans , Informed Consent/legislation & jurisprudence
15.
G Ital Nefrol ; 36(5)2019 Sep 24.
Article It | MEDLINE | ID: mdl-31580541

Conflicts are situations in which two or more people come into disagreement: they are an integral part of social life caused by the inability to find a solution to a dispute. Conflicts are constantly present within families and in all social organizations; in the health sector, they are part of the daily routine. The most common causes of conflict are the lack of resources and the divergence in objectives. All conflicts can quickly escalate, so it is essential to recognize them in order to defuse them as soon as possible. Doctors, as managers, must recognize the early signs of latent conflict in order to better manage them and possibly use them in order to stimulate change in the organization.


Communication , Delivery of Health Care , Dissent and Disputes , Negotiating , Humans , Interpersonal Relations
17.
G Ital Nefrol ; 36(4)2019 Jul 24.
Article It | MEDLINE | ID: mdl-31373463

People with a chronic kidney condition can live with their disease for several years, during which the illness becomes "an integral aspect of life" and requires "an arduous and continuous process of adaptation at multiple levels: cognitive, emotional and physical". Often, communicating with doctors is not helpful to these patients in understanding what is happening and reorganizing their lives, as ineffective communication strategies are employed. It is in fact necessary to overcome obstacles such as the use of incomprehensible technical language, ambiguity, the lack of communication training and the abundance of stressful situations. Chronically ill patients have the right to be informed in a simple, clear and impartial way about their condition and its possible treatments; this information will help them manage their kidney disease, "accept" it and find the motivation to adhere to medical prescriptions over time.


Communication Barriers , Nephrology , Nurse-Patient Relations , Physician-Patient Relations , Renal Dialysis/psychology , Renal Insufficiency, Chronic/psychology , Burnout, Professional , Communication , Humans , Life Change Events , Patient Education as Topic , Renal Insufficiency, Chronic/therapy
18.
G Ital Nefrol ; 36(4)2019 Jul 24.
Article It | MEDLINE | ID: mdl-31373464

Cardiovascular and renal diseases are one of the main health problems in all industrialized countries. Their incidence is constantly increasing due to the aging of the population and the greater prevalence of obesity and type 2 diabetes. Clinical evidence suggests that aldosterone and the activation of mineralocorticoid receptors (MR) have a role in the pathophysiology of cardiovascular and renal diseases. Moreover, clinical studies demonstrate the benefits of mineralocorticoid receptor antagonists (MRAs) on mortality and progression of heart and kidney disease. In addition to renal effects on body fluid homeostasis, aldosterone has multiple extrarenal effects including the induction of inflammation, vascular rigidity, collagen formation and stimulation of fibrosis. Given the fundamental role of MR activation in renal and cardiac fibrosis, effective and selective blocking of the signal with MRAs can be used in the clinical practice to prevent or slow down the progression of heart and kidney diseases. The aim of the present work is to review the role of MRAs in light of the new evidence as well as its potential use as an antifibrotic in chronic kidney disease (CKD). The initial clinical results suggest that MRAs are potentially useful in treating patients with chronic kidney disease, particularly in cases of diabetic nephropathy. We don't yet have efficacy and safety data on the progression of kidney disease up to the end stage (ESRD) and filling this gap represents an important target for future trials.


Aldosterone/physiology , Mineralocorticoid Receptor Antagonists/therapeutic use , Renal Insufficiency, Chronic/drug therapy , Body Fluids/physiology , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/etiology , Clinical Trials as Topic , Cytokines/metabolism , Diabetic Nephropathies/drug therapy , Eplerenone/therapeutic use , Fibrosis/etiology , Heart/drug effects , Heart Diseases/etiology , Homeostasis , Humans , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Naphthyridines/therapeutic use , Receptors, Mineralocorticoid/metabolism , Spironolactone/therapeutic use
19.
G Ital Nefrol ; 36(2)2019 Apr.
Article It | MEDLINE | ID: mdl-30983173

The Doctor-Patient relationship is of fundamental importance in the field of care and continues to undergo profound transformations. In ancient times the doctor was "authoritarian": the patient was considered a passive element, incapable of understanding, knowing and acting for his own health. The doctor then became a "paternalistic" figure and it is only recently that the patient has become a responsible subject who interacts with the doctor in the definition and evaluation of every health intervention. The patient needs to be actively involved and informed, participating in the therapeutic process and in monitoring the positive and negative effects of the treatment. The doctor needs to communicate in a way that is simple and appropriate in order to avoid misunderstandings, which are very common as patients and doctors can often attribute different meanings to certain words. Doctors need to be aware that such a possibility exists and verify that the patient has understood the real meaning of his words. As good communication between doctors and patients is a strategic factor in care, communication courses should be included in any Medical Degree course.


Communication , Patient Participation , Physician-Patient Relations , Comprehension , Humans
20.
G Ital Nefrol ; 36(2)2019 Apr.
Article It | MEDLINE | ID: mdl-30983175

Native arteriovenous fistula is the preferred vascular access because of it does not usually cause infections and seems to be closely related with prolonged patient survival, compared to prosthetic grafts and central venous catheters; it also is cost effective. Venous stenosis is one of the main causes of AVF failure. It is caused by a number of upstream and downstream events. The former group comprises hemodynamic and surgical stressors, inflammatory stimuli and uraemia, while downstream events involve the proliferation of smooth muscle cells and myofibroblasts and the development of neo-intimal hyperplasia. Percutaneous transluminal angioplasty is the gold standard for arteriovenous fistula stenosis. It allows the visualization of the whole vascular circuit and the immediate use of the vascular access for the next dialysis session. Ultrasound-guided percutaneous endovascular angioplasty is a feasible and safe alternative to conventional fluoroscopic technique: it is equally effective in treating arteriovenous fistula stenosis, but it presents the advantage of not using contrast media or ionizing radiation. The aim of this review is to report the latest evidence on cellular and molecular mechanisms that contribute to the development of neo-intimal hyperplasia, as well as the current and future therapeutic perspectives, especially concerning the use of anti-proliferative drugs, and the efficacy of the ultrasound-guided angioplasty in restoring and maintaining the vascular access patency over time.


Angioplasty/methods , Arteriovenous Fistula/therapy , Ultrasonography, Interventional , Angioplasty, Balloon/methods , Constriction, Pathologic/therapy , Drug-Eluting Stents , Humans , Hyperplasia/etiology , Myocytes, Smooth Muscle/pathology , Postoperative Complications/therapy , Renal Dialysis/adverse effects , Stents , Tunica Intima/pathology
...